EUROPEAN QUALITY STANDARDS: Produced according to the highest European quality standards and tested in independent laboratories
In the OASIS 4 study, patients taking Wegovy tablets experienced an average weight loss of approximately 17% (16.6%), compared with 3% in the placebo group , after 64 weeks, when patients stayed on treatment
Patients who monitor only weight and ignore blood sugar, blood pressure, lipid levels, and inflammatory markers miss important signals about when to continue, taper, or adjust treatment
Nonalcoholic fatty liver disease and polycystic ovary syndrome
Concierge MDLA
en 05403669001 LIPC Lipase colorimetric assay en 4 FF000000071D840E FF000000020D620E 05401704190 307 cobas c 111 Product information shown on this page contains elements of the officially released Method Sheet